BioCryst Pharmaceuticals, Inc. http://www.alacrastore.com/company-snapshot/BioCryst_Pharmaceuticals_Inc-1081610 Friday, September 05, 2008 5:01:03 AM 1081610 BioCryst Pharmaceuticals, Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/ccbn/T1914858ccbn/T1914858norm...Ladies and gentlemen, thank you for standing by. Welcome to BioCryst's Second Quarter #### Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. (OPERATOR INSTRUCTIONS) For your information, this conference is being recorded. I would now like to turn the conference call over to Mr. Stuart Grant, BioCryst's Chief Financial Officer. ... 8/7/2008 1:05:00 PMBioCryst Pharmaceuticals54.0000FinalBioCryst Pharmaceuticals Q2 2008 Earnings Conference Call TranscriptBCRX8:30am ETTranscriptT1914858Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-27235230newstex/PRN-0005-27235230xml BIRMINGHAM, Ala., Aug. #, #### (PRNewswire-FirstCall delivered by Newstex) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter ended June ##, ####.Second Quarter #### Financial ResultsFor...0700000007005000040000000400200004002006040160000401604804016018040160010401601304006000040060050701400007014012070030000700300113000000130100001301000513001000130010028/7/2008 8:25:17 AM18000000180040001800800018020000180150001900000019001000PR Newswire USPRN-0005-27235230BIOCRYST PHARMACEUTICALS INCJon P StonehouseStuart GrantWilliam P SheridanBCRXNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-27072328newstex/PRN-0005-27072328xml BIRMINGHAM, Ala., Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its second quarter #### financial results will be released on Thursday, August #, ####. Following...07000000070050000400000004002000040020060401600004016048040160180401600107014000070140121300000013010000130100057/31/2008 11:23:42 AM180000001800400018008000PR Newswire USPRN-0005-27072328BIOCRYST PHARMACEUTICALS INCJon P StonehouseStuart GrantBCRXNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26065621newstex/PRN-0005-26065621xml BIRMINGHAM, Ala., Jun. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that William P. Sheridan, MB BS, has been appointed Chief Medical Officer of BioCryst, effective...07000000070050000400000004002000040020060701400007014012070140081300000013010000130100056/18/2008 9:26:12 AM180000001802000018007000PR Newswire USPRN-0005-26065621AMGEN INCBIOCRYST PHARMACEUTICALS INCJon P StonehouseAMGNBCRXNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1821691ccbn/T1821691norm...The net loss for the quarter was $##.# million, or $#.## per share, compared to a net loss of $#.# million, or $#.## per share, for the quarter ended March ##, ####. R&D expenses for the first quarter were $##.# million compared to $##.# million in the first quarter of ####. The increase in R&D expenses is attributable to an increase in clinical trial related expenses, manufacturing costs for our lead product candidates and cost related to an increase in the personnel supporting the development of our product candidates. G&A expenses for the first quarter #### were $#.# million compared to $#.# million in the first quarter of ####. The increase in G&A expenses is based on an increase in professional fees and personnel related costs. As of March ##, ####, the Company had cash, cash equivalents and investments of $##.# million. ####, we expect our net cash used to be between $## million and $## million, and this is in line with our previous guidance. This [burn] rate could vary significantly... 5/8/2008 2:08:00 PMBioCryst Pharmaceuticals54.0000FinalQ1 2008 BioCryst Pharmaceuticals Earnings Conference Call TranscriptBCRX8:30am ETTranscriptT1821691Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/bir/209678bir/209678normBioCryst Pharmaceuticals Inc.United StatesManufacturing: Development of pharmaceuticals for the treatment of viral, inflammatory, autoimmune and cardiovascular diseases and disorders.283632541417CGBCRX3/26/2008 6:18:00 AM209678Company Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/ccbn/T1783804ccbn/T1783804norm...Ladies and gentlemen, thank you for standing by. Welcome to BioCryst fourth-quarter and fiscal-year #### financial results and corporate update conference call. At this time all participants are in a listen-only mode. Later we will open up the call for your questions. (OPERATOR INSTRUCTIONS) Please note this conference is being recorded. I would like to turn the conference over to Mr. Stuart Grant, BioCryst's Chief Financial Officer. ... 3/4/2008 10:04:00 AMBioCryst Pharmaceuticals54.0000FinalQ4 2007 BioCryst Pharmaceuticals Earnings Conference Call TranscriptBCRX8:30am ETTranscriptT1783804Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1748893ccbn/T1748893norm1/24/2008 5:07:00 PMBioCryst Pharmaceuticals54.0000FinalBioCryst Updates Peramivir Clinical Development Plan TranscriptBCRX8:00am ET...Good morning and welcome to the BioCryst conference call. For your information, all participants will be in a listen-only mode. There will be an opportunity for you to ask questions at the end of today's presentation. (OPERATOR INSTRUCTIONS) This conference is being recorded. I would like to turn the conference over to Jon Nugent. Sir, please begin. ... TranscriptT1748893Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1547410ccbn/T1547410norm12/31/2007 5:21:09 PMBioCryst Pharmaceuticals54.0000FinalQ1 2007 BioCryst Pharmaceuticals Earnings Conference Call TranscriptBCRX10:00am ET...Good day, everyone, and welcome to the BioCryst Pharmaceuticals first quarter #### financial results conference call. Today's call is being recorded. At this time I'd like to turn the call over to John Nugent, VP of Investor Relations. Please go ahead, sir. ... TranscriptT1547410Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1689752ccbn/T1689752norm11/8/2007 2:07:00 PMBioCryst Pharmaceuticals54.0000FinalQ3 2007 BioCryst Pharmaceuticals Earnings Conference Call TranscriptBCRX10:00am ET... - BioCryst Pharmaceuticals - SVP, CFO Thanks, Jon. Good morning, and thanks for joining our call. As Jon mentioned, the purpose of this call is to discuss the third quarter of #### financial results and provide an update to our corporate programs. Our press release issued this morning provides a detailed explanation of our third quarter #### financial results, but I will summarize some of the main points for you. BioCryst reported revenues of $##.# million in the third quarter of #### compared to $#.# million in the third quarter last year. This increase is directly related to revenues from our contract with HHS for the development of peramivir. Research and development expenses were $##.# million in the third quarter of #### compared with $##.# million in the third quarter of ####. This increase is primarily due to an increase in clinical trial related expenses and manufacturing costs for our lead drug candidates. ... TranscriptT1689752Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1654154ccbn/T1654154norm9/20/2007 9:05:00 AMBioCryst Pharmaceuticals54.0000FinalBioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza TranscriptBCRX5:00pm ET...BioCryst has no obligation to update or revise these statements. BioCryst cautions that you should not place undue reliance on these forward-looking statements. I'd now like to turn the call over to Jon Stonehouse, President and CEO of BioCryst. ... TranscriptT1654154Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1630445ccbn/T1630445norm9/7/2007 7:04:00 PMBioCryst Pharmaceuticals54.0000FinalBioCryst Pharmaceuticals at BioCentury's: NewsMakers in the Biotech Industry Conference TranscriptBCRX2:00pm ET...So, good afternoon. It's my pleasure to introduce BioCryst Pharmaceuticals, the next presenting company. BioCryst is in the process of initiating a pivotal study for their flagship PNP inhibitor, Fodosine, in patients with CTCL. The company also has ongoing programs in CLL, transplantation and influenza and has multiple partnerships with companies such as Roche and Mundipharma. The company also successfully raised $## million in a private placement recently, now has probably north of $### million in cash. Jon will correct me when he comes up. Presenting for the company is BioCryst's CEO Jon Stonehouse. Just as a reminder for all of you, the breakout session is right after the presentation in Room ###. Without further ado. ... TranscriptT1630445Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/srp/19767srp/19767norm...Address:#### Parkway Lake Drive, Birmingham, Alabama ##### Incorporated:DelawareWeb Site: www.biocryst.comSIC Classification: Biological Products, Except Diagnostic Substances (####) Business Description: BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on designing, optimizing and developing novel small molecule pharmaceuticals that block key enzymes essential for cancer, cardiovascular diseases and viral infections. The company's most advanced drug candidate is an investigational purine nucleoside phosphorylase (PNP) inhibitor for the treatment of T-cell mediated disorders. ... 1976709058V103BCRX10/6/2006 12:23:00 PM19767Credit & Investment ResearchSharkRepellent.net